vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and FULL HOUSE RESORTS INC (FLL). Click either name above to swap in a different company.
FULL HOUSE RESORTS INC is the larger business by last-quarter revenue ($75.4M vs $71.7M, roughly 1.1× Adaptive Biotechnologies Corp). FULL HOUSE RESORTS INC runs the higher net margin — -16.4% vs -18.9%, a 2.5% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (51.0% vs 3.4%). FULL HOUSE RESORTS INC produced more free cash flow last quarter ($10.7M vs $1.4M). Over the past eight quarters, Adaptive Biotechnologies Corp's revenue compounded faster (30.8% CAGR vs 3.9%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
Full House Resorts, Inc. is an American casino developer and operator based in Summerlin South, Nevada. The company currently operates five casinos. It is known for the involvement of Gulfstream Aerospace founder Allen Paulson, who was CEO from 1994 to 2000, and former Chrysler chairman Lee Iacocca, who was a major investor in the company from 1995 to 2013. Dan Lee has been CEO since late 2014.
ADPT vs FLL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.7M | $75.4M |
| Net Profit | $-13.6M | $-12.4M |
| Gross Margin | 74.6% | 93.1% |
| Operating Margin | -17.8% | -1.3% |
| Net Margin | -18.9% | -16.4% |
| Revenue YoY | 51.0% | 3.4% |
| Net Profit YoY | 59.7% | -0.6% |
| EPS (diluted) | $-0.08 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.7M | $75.4M | ||
| Q3 25 | $94.0M | $78.0M | ||
| Q2 25 | $58.9M | $73.9M | ||
| Q1 25 | $52.4M | $75.1M | ||
| Q4 24 | $47.5M | $73.0M | ||
| Q3 24 | $46.4M | $75.7M | ||
| Q2 24 | $43.2M | $73.5M | ||
| Q1 24 | $41.9M | $69.9M |
| Q4 25 | $-13.6M | $-12.4M | ||
| Q3 25 | $9.5M | $-7.7M | ||
| Q2 25 | $-25.6M | $-10.4M | ||
| Q1 25 | $-29.9M | $-9.8M | ||
| Q4 24 | $-33.7M | $-12.3M | ||
| Q3 24 | $-32.1M | $-8.5M | ||
| Q2 24 | $-46.2M | $-8.6M | ||
| Q1 24 | $-47.5M | $-11.3M |
| Q4 25 | 74.6% | 93.1% | ||
| Q3 25 | 80.7% | 93.2% | ||
| Q2 25 | 69.4% | 93.5% | ||
| Q1 25 | 67.6% | 93.4% | ||
| Q4 24 | 62.0% | 92.1% | ||
| Q3 24 | 64.1% | 92.2% | ||
| Q2 24 | 55.3% | 92.4% | ||
| Q1 24 | 56.9% | 92.3% |
| Q4 25 | -17.8% | -1.3% | ||
| Q3 25 | 10.9% | 4.4% | ||
| Q2 25 | -42.5% | -0.1% | ||
| Q1 25 | -56.4% | 1.0% | ||
| Q4 24 | -71.3% | -1.9% | ||
| Q3 24 | -70.3% | 3.2% | ||
| Q2 24 | -109.6% | 3.2% | ||
| Q1 24 | -116.5% | -0.9% |
| Q4 25 | -18.9% | -16.4% | ||
| Q3 25 | 10.2% | -9.8% | ||
| Q2 25 | -43.5% | -14.0% | ||
| Q1 25 | -56.9% | -13.0% | ||
| Q4 24 | -71.0% | -16.9% | ||
| Q3 24 | -69.1% | -11.2% | ||
| Q2 24 | -107.0% | -11.7% | ||
| Q1 24 | -113.5% | -16.1% |
| Q4 25 | $-0.08 | $-0.35 | ||
| Q3 25 | $0.06 | $-0.21 | ||
| Q2 25 | $-0.17 | $-0.29 | ||
| Q1 25 | $-0.20 | $-0.27 | ||
| Q4 24 | $-0.22 | $-0.34 | ||
| Q3 24 | $-0.22 | $-0.24 | ||
| Q2 24 | $-0.31 | $-0.25 | ||
| Q1 24 | $-0.33 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.5M | $40.7M |
| Total DebtLower is stronger | — | $473.6M |
| Stockholders' EquityBook value | $218.8M | $2.5M |
| Total Assets | $512.7M | $649.8M |
| Debt / EquityLower = less leverage | — | 186.62× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.5M | $40.7M | ||
| Q3 25 | $55.0M | $30.9M | ||
| Q2 25 | $43.2M | $32.1M | ||
| Q1 25 | $50.6M | $30.7M | ||
| Q4 24 | $47.9M | $40.2M | ||
| Q3 24 | $38.1M | $25.9M | ||
| Q2 24 | $59.8M | $31.1M | ||
| Q1 24 | $71.2M | $25.7M |
| Q4 25 | — | $473.6M | ||
| Q3 25 | — | $473.1M | ||
| Q2 25 | — | $467.5M | ||
| Q1 25 | — | $471.7M | ||
| Q4 24 | — | $468.1M | ||
| Q3 24 | — | $467.4M | ||
| Q2 24 | — | $466.6M | ||
| Q1 24 | — | $465.9M |
| Q4 25 | $218.8M | $2.5M | ||
| Q3 25 | $204.4M | $14.2M | ||
| Q2 25 | $179.7M | $21.2M | ||
| Q1 25 | $190.4M | $31.0M | ||
| Q4 24 | $202.7M | $40.5M | ||
| Q3 24 | $223.8M | $51.8M | ||
| Q2 24 | $241.6M | $59.5M | ||
| Q1 24 | $274.9M | $67.3M |
| Q4 25 | $512.7M | $649.8M | ||
| Q3 25 | $490.6M | $644.4M | ||
| Q2 25 | $496.6M | $651.5M | ||
| Q1 25 | $510.9M | $657.2M | ||
| Q4 24 | $539.4M | $673.3M | ||
| Q3 24 | $558.5M | $668.7M | ||
| Q2 24 | $584.9M | $673.9M | ||
| Q1 24 | $620.3M | $670.4M |
| Q4 25 | — | 186.62× | ||
| Q3 25 | — | 33.30× | ||
| Q2 25 | — | 22.04× | ||
| Q1 25 | — | 15.22× | ||
| Q4 24 | — | 11.56× | ||
| Q3 24 | — | 9.02× | ||
| Q2 24 | — | 7.85× | ||
| Q1 24 | — | 6.92× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.1M | $12.0M |
| Free Cash FlowOCF − Capex | $1.4M | $10.7M |
| FCF MarginFCF / Revenue | 2.0% | 14.1% |
| Capex IntensityCapex / Revenue | 0.9% | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-48.9M | $-2.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $12.0M | ||
| Q3 25 | $-7.1M | $-472.0K | ||
| Q2 25 | $-12.4M | $7.9M | ||
| Q1 25 | $-28.5M | $-9.5M | ||
| Q4 24 | $-12.5M | $14.8M | ||
| Q3 24 | $-27.1M | $-6.7M | ||
| Q2 24 | $-17.3M | $10.1M | ||
| Q1 24 | $-38.4M | $-4.4M |
| Q4 25 | $1.4M | $10.7M | ||
| Q3 25 | $-7.5M | $-5.5M | ||
| Q2 25 | $-13.1M | $4.5M | ||
| Q1 25 | $-29.7M | $-12.3M | ||
| Q4 24 | $-12.6M | $6.9M | ||
| Q3 24 | $-27.4M | $-17.4M | ||
| Q2 24 | $-19.0M | $-1.2M | ||
| Q1 24 | $-39.9M | $-27.0M |
| Q4 25 | 2.0% | 14.1% | ||
| Q3 25 | -8.0% | -7.1% | ||
| Q2 25 | -22.2% | 6.1% | ||
| Q1 25 | -56.7% | -16.4% | ||
| Q4 24 | -26.5% | 9.4% | ||
| Q3 24 | -59.0% | -23.0% | ||
| Q2 24 | -44.1% | -1.6% | ||
| Q1 24 | -95.2% | -38.7% |
| Q4 25 | 0.9% | 1.8% | ||
| Q3 25 | 0.4% | 6.5% | ||
| Q2 25 | 1.1% | 4.5% | ||
| Q1 25 | 2.4% | 3.8% | ||
| Q4 24 | 0.2% | 10.9% | ||
| Q3 24 | 0.7% | 14.1% | ||
| Q2 24 | 4.0% | 15.4% | ||
| Q1 24 | 3.6% | 32.4% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
FLL
| Midwest And South | $58.2M | 77% |
| Food And Beverage | $9.7M | 13% |
| Other Operations | $3.6M | 5% |
| Other | $2.3M | 3% |
| Contracted Sports Wagering | $1.7M | 2% |
